Peroxisome proliferator-activated receptor (PPAR) belongs to the nuclear receptor superfamily, and three isoforms (α, δ and γ) have been identified [1] . PPARα, abundantly expressed in liver, kidney, and heart, plays an important role in the regulation of fatty acid catabolism [2] . The administration of PPARα agonists such as fibrate drugs to rats and mice not only enhances the expression of fatty acid-metabolizing enzymes, but also causes massive hepatic peroxisome proliferation and the development of hepatocellular carcinoma (HCC) [3, 4] . In previous studies, after treatment with PPARα agonists such as clofibrate and Wy-14,643, PPARα-null mice showed neither hepatic peroxisome proliferation nor the development of HCC [5, 6] . These findings indicate that hepatic peroxisome proliferation and hepatocarcinogenesis by PPARα agonist treatment occur exclusively through PPARα.
On the other hand, earlier studies have reported that treatment with rosiglitazone, a selective PPARγ agonist, led to hepatic peroxisome proliferation in ob/ob mice [7] , and that highly selective PPARγ or PPARγ/δ dual agonists induced peroxisome proliferation in mice lacking functional PPARα [8] . These results suggest the existence of PPARα-independent mechanisms that affect peroxisome proliferation. In the present study, we aimed to identify and characterize a novel type of PPARα-independent peroxisome proliferation by using a specific PPARα agonist.
Materials and methods

Animals and fenofibrate treatment
PPARα-null mice on a Sv/129 genetic background were generated as described elsewhere [5] . Twelve-week-old wild-type Sv/129 male mice (n = 12) and age-and sex-matched PPARα-null mice (n = 12) were each divided into two groups, one of 4 which was treated with 25 mg/kg (4 ml/kg corn oil) fenofibrate daily for 10 days by gavage, and the other of which was treated with the same amount of corn oil for 10 days.
After treatment, the mice were killed and their livers were excised and subjected to serial analyses. All animal experiments were conducted in accordance with animal study protocols approved by the Shinshu University School of Medicine.
Cytochemical staining of peroxisomes
Cytochemical staining for peroxisomal catalase was performed following the method described by Novikoff and Goldfischer [9] . Small pieces of liver from each mouse were fixed with 3% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) for 1 h at 4°C, cut into 100-µm sections using an Oxford Vibratome (Oxford Laboratories, Foster City, CA, USA) and post-fixed with 3% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) for 1 h. The sections were incubated in a 3,3'-diaminobenzidine (DAB) reaction medium (0.2% DAB tetrahydrochloride, 50 mM propanediol, pH 9.7, 5 mM KCN, 0.05% H 2 O 2 ) for 1 h at room temperature, then post-fixed with aqueous 1% osmium tetroxide in 0.1 M sodium cacodylate buffer, dehydrated with a graded series of ethanol and acetone, and embedded in Epok 812 (Oken, Tokyo, Japan). The sections (2 µm) were cut with a glass knife, counterstained with 0.1% toluidine blue solution, and examined by light microscopy. Ultrathin sections (0.1 µm) were cut with a diamond knife, collected on grid meshes, stained with lead citrate and uranyl acetate, and examined with a JEM 1200EX II electron microscope (JEOL, Tokyo, Japan) at an accelerating voltage of 80 keV.
Morphometry of hepatic peroxisomes
Morphometric analysis of DAB-stained peroxisomes was carried out using electron (NM011068) [16] ; and FP 5'-CGCCTATTGATGGAACAAGAGACT-3' and RP 5'-TCCAGGTCCCACAGTTTCTACTC-3' for PEX11β (NM011069) [16] . Each mRNA expression level was normalized to the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA expression level, and subsequently normalized to that of wild-type mice fed a control diet. In the case of analysis of dynamin-like protein 1 (DLP1) mRNA, Northern blotting was performed as described previously [2] and hybridized with a 32 P-labeled rat cDNA probe [17] because the mouse cDNA sequence
has not yet been fully confirmed. The band intensity of DLP1 mRNA was quantified densitometrically, normalized to that of GAPDH mRNA, and subsequently normalized to that of wild-type mice fed a control diet.
Statistical analysis
Statistical analysis was performed using SPSS software 11.5J for Windows (SPSS Inc., Chicago, IL, USA). Results were compared using the Student's t-test. A probability value of less than 0.05 was considered to be statistically significant.
Results
mRNA analysis of PPARs and AOX
The hepatic mRNA levels of PPARα and AOX, a representative PPARα target gene, were increased by fenofibrate treatment in wild-type mice, but not in PPARα-null mice (Figs. 1A and D), demonstrating a typical PPARα-dependent response in the present experimental system. The mRNA level of PPARδ was lower in PPARα-null mice than in wild-type mice, and remained unchanged in both genotypes after treatment (Fig. 1B) . The mRNA level of PPARγ mRNA was much lower, approximately one-hundredth, than that of PPARα or PPARδ, when calculated relative mRNA copy numbers toward GAPDH, and remained unchanged in both genotypes after treatment (Fig. 1C) . These results suggest that treatment with fenofibrate, a specific PPARα agonist, induced PPARα target genes.
Morphometric analysis of hepatic peroxisomes
To investigate the relationship between fenofibrate-induced PPARα activation and peroxisome proliferation in the liver, we performed cytochemical DAB staining for peroxisomal catalase. Light microscopic analysis revealed that the number of hepatic peroxisomes was significantly increased in wild-type mice after treatment (Fig. 2, upper   panel) . Additionally, the number of hepatic peroxisomes seemed to be slightly increased by the treatment in PPARα-null mice as well; electron microscopic analysis showed a similar tendency (Fig. 2, lower panel) . Interestingly, large-sized peroxisomes were 8 found in both genotypes after fenofibrate treatment (Fig. 2, lower (Fig. 3A) . The volume density, the most reliable parameter of peroxisome proliferation, was also increased approximately 2-fold in the PPARα-null mice after treatment (3.3 + 0.9% vs.
1.6 + 0.4%, P = 0.008) (Fig. 3B ). These parameters did not differ between the wild-type and PPARα-null mice treated with a control diet. The average diameter of peroxisomes remained unchanged in all groups (Fig. 3C) . These results indicate that treatment with fenofibrate causes hepatic peroxisome proliferation, even in mice lacking functional PPARα, and furthermore, peroxisome enlargement occurs PPARα-independently.
mRNA analysis of PEX11 and DLP1
The number of peroxisomes is controlled by several peroxisome membrane proteins [18] . PEX11 protein, encoded by the PEX11 gene, is one of the major regulators of peroxisome proliferation or division in mammals [18] . To clarify the molecular mechanism of fenofibrate-induced peroxisome proliferation in PPARα-null mice, we first examined the expression of PEX11. The hepatic mRNA level of PEX11α, whose expression is induced by peroxisome proliferators [16, 19] , was markedly 9 increased in the wild-type mice by fenofibrate treatment, but not in similarly-treated PPARα-null mice (Fig. 4A) . The hepatic mRNA level of PEX11β, another isoform of PEX11, remained constant under treatment in both genotypes (Fig. 4B) . Next, we examined the mRNA level of DLP1, a mammalian dynamin-related protein required for peroxisome division [18, 20] . The DLP1 mRNA level was increased approximately 2.5-fold in the fenofibrate-treated wild-type mice (Fig. 4C) . Interestingly, it was also increased approximately 2.4-fold in the PPARα-null mice under the same treatment (Fig.   4C ). These results demonstrate that the increased expression of DLP1, but not PEX11, might be one of the factors associated with the peroxisome proliferation observed in the fenofibrate-treated PPARα-null mice.
Discussion
Detailed high resolution morphometric analysis of hepatic peroxisomes was carried out using electron micrographs of DAB-stained sections. This method has proved to be a suitable and accurate means for analysis of peroxisome proliferation because cytochemical DAB staining can prevent the common underestimation of peroxisomes smaller than 450 nm [10] , and because electron microscopic analysis can minimize error caused by overlapping of peroxisomes found in thick sections [10] . The volume density of peroxisomes in the control wild-type mice was estimated to be 1.4%, which is in good agreement with previously reported values of 1.4% [21] and 1.2% [22] . Thus, the results of morphometric analysis are considered to be reasonable.
For the present mouse treatment, fenofibrate, known as a PPARα ligand, was used.
Surprisingly, peroxisome proliferation was observed in the absence of PPARα (Figs. 2   and 3 ), demonstrating the existence of a newly identified type of PPARα-independent peroxisome proliferation. It is also noteworthy that enlargement of peroxisomes occurs PPARα-independently. Although the precise molecular mechanism of this phenomenon remains unclear, the following explanation may be helpful in understanding it. One of the key molecules associated with peroxisome proliferation is PEX11α, which is closely correlated with PPARα activation (Fig. 4A ) [16, 19] and which probably promotes fenofibrate-induced peroxisome proliferation in wild-type mice; this protein is not induced in PPARα-null mice. This observation might be explained by the fact that PEX11α is a PPARα target gene, but that it is dispensable for peroxisome proliferation according to the phenotype of PEX11α-null mice [23] . Another key mediator of peroxisome proliferation is DLP1, which demonstrates increased expression after treatment with fenofibrate in both wild-type and PPARα-null mice (Fig. 4C) . DLP1 is believed to be required for the division step of peroxisomes [18, 20] . The
PPARα-independent increase in DLP1 is consistent with the possibility that this protein causes peroxisome proliferation in both genotypes. DLP1 expression is increased in rat livers treated with bezafibrate [20] , a potent PPARδ agonist and a moderate PPARα agonist [24] . However, it remains unclear whether DLP1 contributes to peroxisome proliferation in either genotype through PPARδ activation, because fenofibrate is PPARα agonist and is not known to activate PPARδ. On the other hand, it is clear that PPARα-independent enlargement of peroxisomes has little relevance to PPARα-dependent increases in peroxisomal matrix proteins such as AOX (Fig. 1D ) or peroxisome-forming membrane proteins such as PEX11α (Fig. 4A) . Further experimentation is required in order to understand the detailed molecular mechanisms of PPARα-independent peroxisome proliferation.
Hepatic peroxisome proliferation is considered to be strong proof of PPARα 11 activation in rats and mice [25] , and has been used as an important standard to estimate susceptibility to rodent HCC in the development of new candidate compounds with PPARα activation and serum lipid-lowering activity. However, the present results indicate that peroxisome proliferation is not necessarily a suitable biological marker of continuous PPARα activation. Therefore, caution should be exercised when attempting to assess the risk of hepatocarcinogenesis based solely on the presence of peroxisome proliferation in short-term bioassays.
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